Toxoplasma gondii SRS34A mRNA vaccine elicits protective immune response against toxoplasmosis in mice
Frontiers in Microbiology · 19.11.2026 · 17
DOI: 10.3389/fmicb.2026.1942102 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Microbiology, online erschienen am 19.11.2026. Verfasst von Jichao Yang und 9 weiteren Autor:innen. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Toxoplasmosis is a prevalent zoonotic parasitic disease caused by Toxoplasma gondii , which infects nearly all warm-blooded animals including humans. It causes substantial economic losses to the livestock industry and poses a considerable threat to public health. Currently, therapeutic options for toxoplasmosis remain highly limited, and no safe and effective vaccine is widely licensed for human use. In this study, we developed a LNP encapsulated mRNA vaccine encoding SRS34A, a surface localized protein highly expressed across developmental stages of T. gondii . ICR mice ( n = 5 per group) were intramuscularly immunized three times at a dose of 10 μg per mouse with the SRS34A-mRNA-LNP vaccine. Vaccination elicited a balanced Th1/Th2 immune response, as evidenced by high SRS34A-specific IgG titers and significantly elevated levels of both Th1-type cytokines (IL-12, TNF-α, IFN-γ) and the Th2-type cytokine IL-4. Challenge assays showed that vaccination conferred partial protection against T. gondii infection. In the chronic infection model with 100 type II ME49 tachyzoites (i.p.), vaccinated mice achieved an 80% survival rate versus 60% in controls, although the survival difference was not statistically significant. Meanwhile, both the number of brain cysts in vaccinated mice were significantly reduced compared with controls. For acute infection with the virulent type I RH strain, vaccination significantly prolonged mouse survival at a challenge dose of 100 tachyzoites (i.p.), and markedly reduced peritoneal parasite burden in a separate experiment with 10 5 RH tachyzoites. In conclusion, the SRS34A-mRNA-LNP vaccine effectively induces SRS34A-specific humoral immunity and a balanced Th1/Th2 cytokine response, and confers partial protection against both acute and chronic T. gondii infection in mice. These findings support SRS34A as a promising candidate for further development of mRNA vaccines against toxoplasmosis.
Zitieren
APA
Yang, J., Lin, J., Yang, X., Li, S., Dai, R., Zhu, X., Lin, X., Zou, W., Qiu, G., & Huang, C. (2026). Toxoplasma gondii SRS34A mRNA vaccine elicits protective immune response against toxoplasmosis in mice. Frontiers in Microbiology, 17. https://doi.org/10.3389/fmicb.2026.1942102
Vancouver
Yang J, Lin J, Yang X, Li S, Dai R, Zhu X, et al. Toxoplasma gondii SRS34A mRNA vaccine elicits protective immune response against toxoplasmosis in mice. Frontiers in Microbiology. 2026;17. doi:10.3389/fmicb.2026.1942102
BibTeX
@article{Yang2026,
author = {Yang, Jichao and Lin, Junhong and Yang, Xuke and Li, Senyang and Dai, Ruolin and Zhu, Xiangting and Lin, Xingcheng and Zou, Weijie and Qiu, Guohua and Huang, Cuiqin},
title = {Toxoplasma gondii SRS34A mRNA vaccine elicits protective immune response against toxoplasmosis in mice},
journal = {Frontiers in Microbiology},
year = {2026},
volume = {17},
doi = {10.3389/fmicb.2026.1942102}
}
EUVIMED